Smok3a Activators
Smok3a Activators encompass a diverse group of chemical compounds that enhance Smok3a's function through various cellular mechanisms. Forskolin and IBMX both elevate intracellular cAMP levels, which in turn activate PKA, a kinase capable of phosphorylating Smok3a, thereby enhancing its activity. Analogously, PMA stimulates PKC, another kinase that might phosphorylate Smok3a, while A23187 and Ionomycin increase intracellular calcium, triggering calcium-dependent kinases to potentially enhance Smok3a activity. EGCG's role as a tyrosine kinase inhibitor could lead to an indirect increase in Smok3a's activity by reducing competitive signaling interference, thereby allowing Smok3a pathways to be more functional.
Continuing with the theme of pathway-specific activation, LY294002 and Wortmannin, as PI3K inhibitors, might indirectly increase Smok3a activity by modulating AKT signaling, which can have repressive effects on Smok3a. Similarly, U0126 and SB203580 target the MAPK/ERK and p38 MAPK pathways, respectively, potentially favoring Smok3a activation by diminishing competing pathway signals.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin raises intracellular cyclic AMP (cAMP) levels by activating adenylate cyclase, which in turn enhances Smok3a activity by triggering cAMP-dependent protein kinase A (PKA) pathways. Activation of PKA can result in phosphorylation of Smok3a or its associated proteins, leading to increased activity of Smok3a. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX, a non-selective phosphodiesterase inhibitor, prevents the degradation of cAMP, thereby maintaining enhanced PKA signaling. This sustained PKA activity can lead to the phosphorylation of substrates that interact with Smok3a, indirectly increasing its activity. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram selectively inhibits phosphodiesterase 4 (PDE4), leading to an increase in cAMP levels. The subsequent activation of PKA may then phosphorylate Smok3a or its interacting partners, promoting Smok3a's functional activity. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride acts as a GSK-3 inhibitor, potentially leading to the de-repression of pathways that Smok3a is involved with, thereby enhancing Smok3a's activity indirectly through the modulation of GSK-3 mediated signaling. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Anisomycin is a potent activator of JNK/SAPK pathways, which could lead to the modulation of stress response pathways affecting Smok3a, thereby potentially enhancing its activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), leading to the phosphorylation of downstream proteins that could include Smok3a or its associated proteins, thereby enhancing Smok3a's activity indirectly through PKC-mediated signaling events. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 inhibits p38 MAP kinase, which may enhance Smok3a activity by reducing p38 MAPK pathway mediated inhibition on the pathways Smok3a is involved in, thus indirectly promoting Smok3a's functional role. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic acid is a protein phosphatase inhibitor, leading to increased phosphorylation within the cell. This hyperphosphorylated environment may indirectly enhance Smok3a activity by affecting the phosphorylation state of proteins within Smok3a's signaling network. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG has kinase inhibitory activity, which may lead to altered signaling pathways and enhance Smok3a activity by changing the phosphorylation state of proteins in Smok3a's signaling cascade. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
Sphingosine-1-phosphate acts through G-protein coupled receptors to initiate signaling cascades that can culminate in the activation of Smok3a either through direct protein-protein interactions or via secondary messengers. | ||||||